Advancing our disruptive technology platforms
Creative Medical Technology Holdings, Inc. (CELZ) is a biotechnology company committed to improving patient lives via a regenerative approach to immunology, endocrinology, urogynecology, and orthopedics.
Our company is supported by a leadership team with extensive experience, a novel scientfically based patent portfolio and a well defined business strategy.
Creative Medical Technology Holdings, Inc. is advancing multiple unique platforms—supercharged autologous therapy, enhanced allogenic cell platform, reprogrammed
cells, and rapid autologous therapies.
Our company offers new solutions to medical conditions with its innovative regenerative medicine and immunotherapy technologies.
The company benefits from an experienced management team as well as a base of talented scientific & medical consultants with vast industry experience.
Our innovative technologies are disruptive in the field of regenerative medicine and immunotherapy.
Creative Medical Technology Holdings, Inc. continues to develop a robust development pipeline.
Our Innovative regenerative medical technology can treat various conditions, leading to sizable markets.
Creative Medical Technology Holdings, Inc. has developed a robust intellectual property portfolio with technologies to improve patient lives in the areas of immunology, endocrinology, urogynecology, and orthopedics. The company currently has over 60 pending or issued patents.
We work with Not For Profit and For Profit Organizations in the further development of our technologies. As related to Translational Projects we have defined policies and protocols in place that allows for indirect costs up to 25 percent of the direct costs. Direct costs + 25% of direct costs = Total project budget.Learn More
Read about our latest stories in the press.
Interested in learning more?
Connect with us now by filling out our form on our contact page.
ImmCelz® is our first autologous immunotherapy platform that utilizes secreted factors from universal donor cells to supercharge the patient's own immune cells. Our enhanced allogenic cell platform, AlloStemTM, utilizes an unique perinatal derived tissue cell to treat a variety of indications. iPSCELZTM, our cellular reprogramming platform, is a developing platform with the potential ability to differentiate any cell type in the body from any patient. The StemSpine®, OvaStem®, and CaverStem® programs utilize our rapid autologous therapy platform.